ArticleJournal of mid-life health
Beyond its Rarity: A 10-year Study on Primary Adenoid Cystic Carcinoma of the Breast from a Tertiary Care Center.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adenoid cystic carcinoma (AdCC) of the breast is a rare malignancy (~0.1%), affecting women in their 50s-60s. It presents as a palpable mass with tubular, cribriform, and solid patterns and shows biphasic differentiation. C-Kit expression supports diagnosis. Despite its triple-negative status, AdCC has a favorable prognosis, except in solid-basaloid variants. Materials and Methods: This retrospective study was conducted in the Department of Histopathology, Apollo Cancer Center, Chennai, and included all cases of primary breast AdCC diagnosed between January 2014 and December 2024. Results: Twelve female patients were included, with a mean age of 55.5 years. All presented with a breast lump; right and left sides were equally involved, with the upper outer quadrant being the most common site (70%). Surgical management included wide local excision (WLE) (45.45%), modified radical mastectomy (36.36%), total mastectomy (9.09%), and chemotherapy/immunotherapy in one patient (9.09%). Multifocality was seen in 16.66% (2/12). Mean tumor size was 2.66 cm, and pT2 stage was most frequent (57.14%). One case showed local recurrence post-WLE; another developed lung metastasis. Histologically, 75% showed all three patterns with solid areas ranging from 10% to 90%. Perineural invasion was seen in 58.33% (7/12) and lymphovascular invasion in 16.66% (2/12). Most tumors were Nottingham Grade 2 (83.33%). All were progesterone receptor and HER2/neu negative; estrogen receptor positivity was seen in two cases. C-Kit was positive in all tested cases. Ki-67 index ranged from 6% to 80%. Conclusion: Breast AdCC shows favorable prognosis. Most cases were pT2, stage IIA, with rare recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.